R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
Tobias Kessler,Tobias Kessler,Anne Berberich,Anne Berberich,Ahmed Sadik,Felix Sahm,Thierry Gorlia,Christoph Meisner,Dirk C Hoffmann,Dirk C Hoffmann,Dirk C Hoffmann,Antje Wick,Philipp Kickingereder,Petra Rübmann,Martin Bendszus,Christiane A. Opitz,Michael Weller,Martin J. van den Bent,Roger Stupp,Frank Winkler,Frank Winkler,Alba A. Brandes,Andreas von Deimling,Michael Platten,Wolfgang Wick,Wolfgang Wick +25 more
TL;DR: Gliomas evade current therapies through primary and acquired resistance and the effect of temozolomide is mainly restricted to methylguanin‐O6-methyltransferase promoter (MGMT) promoter hypermethylated tumors.
Journal ArticleDOI
Primetime for antiangiogenic therapy
Ghazaleh Tabatabai,Roger Stupp +1 more
TL;DR: The results of recent clinical trials in the treatment of gliomas are summarized, mechanisms of resistance arising under angiogenesis inhibition are pointed towards, and the challenges for the future are discussed.
Journal ArticleDOI
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status
Kenney Roy Roodakker,Tamador Elsir,Per Henrik Edqvist,Daniel Hägerstrand,Joseph W. Carlson,Malgorzata Lysiak,Roger Henriksson,Fredrik Pontén,Johan Rosell,Peter Söderkvist,Roger Stupp,Elena Tchougounova,Monica Nistér,Annika Malmström,Anja Smits,Anja Smits +15 more
TL;DR: It is concluded that PROX1 is a new prognostic biomarker for 1p19q non-codeleted high-grade astrocytomas that have progressed from pre-existing low-grade tumors and harbor IDH mutations.
Journal ArticleDOI
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Linda Dirven,Jammbe Z. Musoro,Corneel Coens,Jaap C. Reijneveld,Martin J B Taphoorn,Florien W. Boele,Florien W. Boele,Mogens Groenvold,Mogens Groenvold,Martin J. van den Bent,Roger Stupp,Galina Velikova,Kim Cocks,Mirjam A. G. Sprangers,Madeleine King,Hans-Henning Flechtner,Andrew Bottomley +16 more
TL;DR: In this article, mean change method and linear regression were applied to estimate minimally important differences (MIDs) for interpreting within-group change and between-group differences in change over time.
Journal ArticleDOI
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
Emilie Le Rhun,Els Genbrugge,Roger Stupp,Olivier Chinot,L. Burt Nabors,Timothy F. Cloughesy,David A. Reardon,Wolfgang Wick,Thierry Gorlia,Michael Weller +9 more
TL;DR: Anticoagulant use was not associated with improved OS and may not exert relevant anti-tumour properties in glioblastoma, and no survival association was established for anti-platelet agent use.